New Haven Pharmaceuticals (NHP), a privately-owned speciality pharmaceuticals company based in Branford, CT, in the US, has strengthened its management team with the appointment of two experienced pharmaceutical executives to newly-created positions: Jeffrey Patrick as Chief Scientific Officer, and Michael Richardson as Chief Business Officer.
Patrick joins NHP from Mallinckrodt Pharmaceuticals (MNK) (formerly Covidien), where he most recently was Global Vice President of Medical Affairs. He previously held leadership positions in several other major pharmaceutical companies, including Sanofi, Actelion, and Gilead.
Richardson brings nearly 20 years of experience in pharmaceutical marketing, sales, product planning, business development and licensing to the newly-created position of Chief Business Officer. He joins NHP from Grünenthal USA, where he was most recently Head of Commercial Affairs.
He has also held leadership roles at Grünenthal, Aton, Cephalon, Johnson & Johnson, and Merck.
NHP is developing Durlaza, an investigational novel aspirin product designed to be slowly released into the bloodstream over 24 hours, a longer period of time than currently available aspirin products.
The company submitted a New Drug Application to the US FDA in September for Durlaza to reduce the risk of stroke or acute cardiac events in patients who have suffered a prior stroke or acute cardiac event.
